Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
cardiovascular disease
dyslipidemia
hypertension
major cardiovascular events
polypill
Journal
Vascular health and risk management
ISSN: 1178-2048
Titre abrégé: Vasc Health Risk Manag
Pays: New Zealand
ID NLM: 101273479
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
22
08
2023
medline:
19
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percentages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
Sections du résumé
Background
UNASSIGNED
Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention.
Methods
UNASSIGNED
A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety.
Results
UNASSIGNED
From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percentages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar.
Conclusion
UNASSIGNED
The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
Identifiants
pubmed: 37719697
doi: 10.2147/VHRM.S421024
pii: 421024
pmc: PMC10504901
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-615Informations de copyright
© 2023 Lopez-Lopez et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
PLoS One. 2015 Apr 24;10(4):e0122112
pubmed: 25909595
N Engl J Med. 2022 Sep 15;387(11):967-977
pubmed: 36018037
J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82
pubmed: 25193393
Cerebrovasc Dis Extra. 2020;10(3):166-173
pubmed: 33176324
Glob Heart. 2021 Sep 10;16(1):63
pubmed: 34692387
Hypertension. 2020 Jun;75(6):1334-1357
pubmed: 32370572
Glob Heart. 2019 Mar;14(1):3-16.e1
pubmed: 30502220
J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371
pubmed: 36368511
JAMA Cardiol. 2020 Sep 1;5(9):1011-1018
pubmed: 32936272
BMJ. 2003 Jun 28;326(7404):1427
pubmed: 12829555
Lancet. 2020 Mar 7;395(10226):795-808
pubmed: 31492503
J Comp Eff Res. 2021 Sep;10(13):975-985
pubmed: 34196593
Int J Cardiol. 2015 Feb 15;181:193-9
pubmed: 25528311
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Prog Cardiovasc Dis. 2022 Jul-Aug;73:48-55
pubmed: 35114251
Am J Med. 2012 Sep;125(9):882-7.e1
pubmed: 22748400
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):463-71
pubmed: 22787067
Lancet. 2019 Aug 24;394(10199):672-683
pubmed: 31448738
BMJ. 2014 May 27;348:g3318
pubmed: 24868083
Lancet. 2009 Apr 18;373(9672):1341-51
pubmed: 19339045
Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720912071
pubmed: 32186246
Clin Cardiol. 2022 Dec;45(12):1220-1228
pubmed: 36116032
JAMA. 2013 Sep 4;310(9):918-29
pubmed: 24002278
BMJ. 2003 Jun 28;326(7404):1419
pubmed: 12829553
Lancet Public Health. 2017 Sep;2(9):e411-e419
pubmed: 29253412
Eur J Prev Cardiol. 2015 Jul;22(7):920-30
pubmed: 24676715
Trials. 2011 Jan 05;12:3
pubmed: 21205325
Int J Cardiol. 2022 Aug 15;361:116-123
pubmed: 35569611
Cureus. 2020 Jul 23;12(7):e9349
pubmed: 32742886
Lancet. 2021 Sep 25;398(10306):1133-1146
pubmed: 34469765
N Engl J Med. 2021 Jan 21;384(3):216-228
pubmed: 33186492
Am J Prev Med. 2022 Sep;63(3):440-449
pubmed: 35613977